



romiplostim 125 micrograms, 250 micrograms, 500 micrograms powder for solution for injection (Nplate®)

Amgen Ltd

11 January 2019

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

romiplostim (Nplate®) is accepted for restricted use within NHSScotland.

Indication under review: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)

SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding.

Romiplostim has previously been accepted for restricted use in adults with ITP. The licence has now been extended to use in children from the age of 1 year.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 12 November 2018.

**Chairman
Scottish Medicines Consortium**